Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(100.0%)
2Total
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01198860Unknown

Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B

Role: lead

NCT05043324Phase 4Completed

Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

Role: lead

NCT05178303Phase 4Completed

Composition for Treating Cirrhosis and Liver Cancer (SB-1121)

Role: lead

All 3 trials loaded